Results 41 to 50 of about 19,833 (230)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

Quality of life in children with primary antibody deficiency. [PDF]

open access: yes, 2014
Primary antibody deficiency disorders (PADs) can have an excellent outlook if diagnosed early and treated appropriately, but require lifelong treatment with immunoglobulin replacement.
Allwood, Z   +8 more
core   +1 more source

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

open access: yesAdvanced Science, EarlyView.
ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders.
Suneesh Thilak   +9 more
wiley   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo   +38 more
wiley   +1 more source

Unmasking Primary Immunodeficiency After Rituximab

open access: yesJournal of Human Immunity
IntroductionRituximab, an anti-CD40 antibody, is a commonly used B cell-depleting therapy. We present a case that illustrates the unveiling of an underlying common variable immune deficiency (CVID) after completion of rituximab therapy.Case ...
Carson Ercanbrack   +3 more
doaj   +1 more source

A retrospective study on 195 horses with contaminated and infected synovial cavities [PDF]

open access: yes, 2009
This study analyzes the clinical aspects of contaminated and infected synovial cavities in horses and evaluates their prognosis after treatment. The medical records of 195 affected horses referred between June 1999 and July 2004 were reviewed. Twenty-six
Dewulf, Jeroen   +5 more
core   +1 more source

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

open access: yesArthritis &Rheumatology, EarlyView.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng   +6 more
wiley   +1 more source

Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era

open access: yesFrontiers in Oncology
BackgroundElderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) undergoing reduced intensity R-CHOP therapy are at a heightened risk of acquiring infections, notably coronavirus disease 2019 (COVID-19) infection.
Dong Won Baek   +7 more
doaj   +1 more source

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease

open access: yesFrontiers in Immunology, 2021
ObjectiveTo evaluate the characteristics of patients with autoimmune disease with hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes, including those who commenced immunoglobulin replacement therapy.MethodsPatients ...
Joanna Tieu   +13 more
doaj   +1 more source

Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency. [PDF]

open access: yes, 1988
Human-human B cell hybridomas constructed from B lymphocytes of common variable immunodeficiency (CVI) patients and the nonsecreting cell line WIL2/729 HF consistently secrete low levels of Ig and appear to retain a defect characteristic of the CVI ...
Adelman, DC   +5 more
core  

Home - About - Disclaimer - Privacy